Answers are grounded in this paper and cite their sources.
: A precision medicine strategy based on robust molecular predictors of outcome is desirable in the development of investigational small molecules for DLBCL. Novel monoclonal and bispecific antibodies may be offered to (i) relapsed/refractory patients ineligible for CAR-T cells because of comorbidities, and (ii) younger patients before CAR-T cell infusion to reduce a high tumor burden. A focus on the optimal sequencing of the emerging DLBCL drugs is appropriate and necessary.
No takes yet. Share an insight, caveat, or question.
Patriarca et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: